Cantor Fitzgerald analyst Kristen Kluska upgraded Supernus (SUPN) to Overweight from Neutral with a price target of $42, up from $36. The firm believes Qelbree is redefining the treatment landscape for attention-deficit/hyperactivity disorder. The analyst cites a more positive outlook on Qelbree following its 25 physician survey for the upgrade. Cantor says 72% of those surveyed indicated they plan to prescribe more non-stimulants in the future, and it believes Qelbree could be a big part of this growth.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald
- Supernus announces expiration of HSR waiting period for Sage Therapeutics
- Sage Therapeutics cutting over 330 jobs, Boston Globe reports
- Supernus Pharmaceuticals Holds Annual Stockholders Meeting
- H.C. Wainwright sees potential competition for Sage from Biogen